BillionToOne, Inc. (BLLN) Stock

BillionToOne, Inc. is a precision diagnostics company specializing in the development of advanced molecular diagnostic tests for healthcare applications. The company’s core innovation is its proprietary single-molecule next-generation sequencing (smNGS) platform, which enables highly sensitive and accurate detection and quantification of DNA molecules at the single-molecule level. This technological breakthrough underpins BillionToOne’s flagship product lines, including UNITY Complete, a non-invasive prenatal screening test that assesses fetal risk for chromosomal aneuploidies, recessive conditions such as sickle cell disease and cystic fibrosis, and fetal antigens, all from a single maternal blood draw. Additionally, the company’s Northstar Select and Northstar Response tests are designed for oncology, offering sensitive liquid biopsy solutions that guide therapy selection and provide longitudinal monitoring of cancer burden. BillionToOne’s molecular counting technologies are intended to address significant unmet needs in both the prenatal and oncology sectors, enabling earlier, safer, and more comprehensive disease detection. With a mission to improve healthcare accessibility and patient outcomes, BillionToOne plays a transformative role in the diagnostics and research segment of the healthcare market, supporting the shift toward personalized and non-invasive medicine.